102 related articles for article (PubMed ID: 25858426)
1. Inhibition of bcr-abl in human leukemic cells with a coiled-coil protein delivered by a leukemia-specific cell-penetrating Peptide.
Bruno BJ; Lim CS
Mol Pharm; 2015 May; 12(5):1412-21. PubMed ID: 25858426
[TBL] [Abstract][Full Text] [Related]
2. Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML.
Miller GD; Woessner DW; Sirch MJ; Lim CS
Mol Pharm; 2013 Sep; 10(9):3475-83. PubMed ID: 23915432
[TBL] [Abstract][Full Text] [Related]
3. TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization.
Huang ZL; Gao M; Ji MS; Tao K; Xiao Q; Zhong L; Zeng JM; Feng WL
Amino Acids; 2013 Feb; 44(2):461-72. PubMed ID: 22782217
[TBL] [Abstract][Full Text] [Related]
4. Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells.
Huang Z; Ji M; Peng Z; Huang S; Xiao Q; Li C; Zeng J; Gao M; Feng W
Biomed Pharmacother; 2011 Jun; 65(3):183-92. PubMed ID: 21641753
[TBL] [Abstract][Full Text] [Related]
5. A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia.
Woessner DW; Eiring AM; Bruno BJ; Zabriskie MS; Reynolds KR; Miller GD; O'Hare T; Deininger MW; Lim CS
Leukemia; 2015 Aug; 29(8):1668-75. PubMed ID: 25721898
[TBL] [Abstract][Full Text] [Related]
6. Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells.
Peng Y; Huang Z; Zhou F; Wang T; Mou K; Feng W
Cell Commun Signal; 2021 Jul; 19(1):71. PubMed ID: 34217296
[TBL] [Abstract][Full Text] [Related]
7. Computational Modeling of Stapled Coiled-Coil Inhibitors Against Bcr-Abl: Toward a Treatment Strategy for CML.
Lima MCP; Hornsby BD; Lim CS; Cheatham TE
bioRxiv; 2023 Nov; ():. PubMed ID: 38014060
[TBL] [Abstract][Full Text] [Related]
8. Cell-penetrating fusion peptides OD1 and OD2 interact with Bcr-Abl and influence the growth and apoptosis of K562 cells.
Wang HX; Xiao H; Zhong L; Tao K; Li YJ; Huang SF; Wen JP; Feng WL
Mol Cell Biochem; 2014 Jan; 385(1-2):311-8. PubMed ID: 24091918
[TBL] [Abstract][Full Text] [Related]
9. Molecular Modeling of Single- and Double-Hydrocarbon-Stapled Coiled-Coil Inhibitors against Bcr-Abl: Toward a Treatment Strategy for CML.
Lima MCP; Hornsby BD; Lim CS; Cheatham TE
J Phys Chem B; 2024 Jul; ():. PubMed ID: 38951498
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.
Gambacorti-Passerini C; le Coutre P; Mologni L; Fanelli M; Bertazzoli C; Marchesi E; Di Nicola M; Biondi A; Corneo GM; Belotti D; Pogliani E; Lydon NB
Blood Cells Mol Dis; 1997 Dec; 23(3):380-94. PubMed ID: 9446752
[TBL] [Abstract][Full Text] [Related]
11. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
12. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
[TBL] [Abstract][Full Text] [Related]
13. Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis.
Dixon AS; Miller GD; Bruno BJ; Constance JE; Woessner DW; Fidler TP; Robertson JC; Cheatham TE; Lim CS
Mol Pharm; 2012 Jan; 9(1):187-95. PubMed ID: 22136227
[TBL] [Abstract][Full Text] [Related]
14. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
Peng Z; Luo HW; Yuan Y; Shi J; Huang SF; Li CL; Cao WX; Huang ZG; Feng WL
Oncol Rep; 2011 May; 25(5):1381-8. PubMed ID: 21369701
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
16. siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
Freire JM; Rego de Figueiredo I; Valle J; Veiga AS; Andreu D; Enguita FJ; Castanho MA
J Control Release; 2017 Jan; 245():127-136. PubMed ID: 27890856
[TBL] [Abstract][Full Text] [Related]
17. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
18. Computational Modeling of Stapled Peptides toward a Treatment Strategy for CML and Broader Implications in the Design of Lengthy Peptide Therapeutics.
Cornillie SP; Bruno BJ; Lim CS; Cheatham TE
J Phys Chem B; 2018 Apr; 122(14):3864-3875. PubMed ID: 29519125
[TBL] [Abstract][Full Text] [Related]
19. The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.
Zhang X; Subrahmanyam R; Wong R; Gross AW; Ren R
Mol Cell Biol; 2001 Feb; 21(3):840-53. PubMed ID: 11154271
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Roy M; Sarkar R; Mukherjee A; Mukherjee S
Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
